Buprenorphine injection is now approved by the FDA for opioid use disorder.

Published Date: 27 May 2023

For the treatment of moderate to severe opioid use disorder, the FDA has approved the extended-release injection drug buprenorphine (Brixadi, Braeburn Inc.).

Read Full News

Latest News

WHO’s Role in Stopping Cross-Border Infections

Recent Ebola and hantavirus outbreaks show how WHO coordination, surveillance, and guidance remain vital when infections move across borders.

Europe’s Health Systems Face a Heat Test

New WHO guidance highlights how extreme heat is straining hospitals, with practical measures now shaping safer care environments across Europe.

ERAS Protocol Optimizes Pediatric Appendectomy Care

A modified ERAS protocol shortened hospital stay without increasing complications after pediatric appendectomy, supporting its use in resource-limited healthcare settings.

Cognitive Rehabilitation Eases Long-COVID Brain Fog

The therapy helps patients achieve small but meaningful goals, from reading for 20 minutes a few times per week to completing short work tasks.

Porcine Corneal Grafts May Ease Donor Cornea Shortages

Porcine corneal grafts offer a potential answer to donor cornea shortages, but researchers urge larger studies to confirm safety, tolerability, and long-term efficacy.

Amgen Fights to Keep Avacopan on Market Amid Rising Concerns

NEJM’s retraction of the key avacopan paper reflects concerns about data used for approval of this autoimmune disease drug, which has been linked to liver injury.

Todays Updates

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

Belzutifan and pembrolizumab together reduced the risk of disease recurrence or death

FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting

Capivasertib plus abiraterone combination lands indication for PTEN-deficient tumors

Talquetamab Regimens Boost Survival in Multiple Myeloma

"Combinations represent additional options for early-line treatment," researcher says

In High-Risk B-Cell ALL, Swapping Out Chemo for Blinatumomab Improves Outcomes

The bispecific T-cell engager also reduced toxicity in newly diagnosed kids

Timely 'Nudges' Can Help Encourage More End-of-Life Conversations in Cancer

A combination of clinician and patient prompts worked best, but talks remained infrequent

Todays Updates

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

Belzutifan and pembrolizumab together reduced the risk of disease recurrence or death

FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting

Capivasertib plus abiraterone combination lands indication for PTEN-deficient tumors

Talquetamab Regimens Boost Survival in Multiple Myeloma

"Combinations represent additional options for early-line treatment," researcher says

In High-Risk B-Cell ALL, Swapping Out Chemo for Blinatumomab Improves Outcomes

The bispecific T-cell engager also reduced toxicity in newly diagnosed kids

Timely 'Nudges' Can Help Encourage More End-of-Life Conversations in Cancer

A combination of clinician and patient prompts worked best, but talks remained infrequent

Latest News

Recent Ebola and hantavirus outbreaks show how WHO coordination, surveillance, and guidance remain vital when infections move across borders.

New WHO guidance highlights how extreme heat is straining hospitals, with practical measures now shaping safer care environments across Europe.

A modified ERAS protocol shortened hospital stay without increasing complications after pediatric appendectomy, supporting its use in resource-limited healthcare settings.

The therapy helps patients achieve small but meaningful goals, from reading for 20 minutes a few times per week to completing short work tasks.

Porcine corneal grafts offer a potential answer to donor cornea shortages, but researchers urge larger studies to confirm safety, tolerability, and long-term efficacy.

NEJM’s retraction of the key avacopan paper reflects concerns about data used for approval of this autoimmune disease drug, which has been linked to liver injury.

News All Time

Women With Food Allergies Face Greater Burden

Food allergies take a lasting toll on quality of life, with women with multiple food allergies facing the greatest burden.

GCA May Often Coexist With Hidden Polymyalgia Rheumatica

A substantial proportion of patients with apparently isolated giant cell arteritis may also have subclinical polymyalgia rheumatica, with distinct disease patterns.

Smell, Taste Disturbances Tied to GLP-1s in Type 2 Diabetes

The absolute risk appears low, but new data suggest small changes in smell and taste with GLP-1 treatment may exceed those already associated with type 2 diabetes.

Lower GI Bleeding: When Is It Safe to Discharge Patients?

The Oakland score offers the greatest discrimination and specificity for identifying patients with lower GI bleeding who can be safely discharged from the ED.

S1 Episode 5: How Many ATTR-CM Patients Are We Still Missing?

From missed red flags to insurance denials, the barriers to ATTR-CM care are multi-level. Drs Alexander and Pino-Moreno break down what’s failing and how to fix it.

Remibrutinib Improves Quality of Life in Urticaria

Remibrutinib benefits patients with chronic spontaneous urticaria in terms of disease control, quality of life, and sleep, with effects sustained for the long term.

Routine Vaccines May Offer Protection Against Uveitis

Routine vaccinations are associated with a significantly reduced risk of developing new-onset idiopathic uveitis, according to a large-scale retrospective cohort study.

US CDC Raises Ebola Outbreak Response to Highest Level

The U.S. CDC raised its response to the Ebola outbreak in the Democratic Republic of Congo to its highest level ⁠on Friday, but said the risk of the disease spreading in the...

Pediatric Renal Trauma, No Surgery for Most

Among kids with renal injuries, most receive nonoperative management; angioembolization yields better results than surgical repair among those with high-grade renal trauma.

Revisiting ERCP Timing: Early vs Urgent in Cholangitis

In most patients with mild-to-moderate cholangitis, performing ERCP within 24-48 hours appears to be as effective as performing it within 24 hours.

EMA Turns Down 3 Therapies Across Oncology, Transplantation

Tacquell, Yartemlea, and Xervyteg failed to secure positive CHMP recommendations after EMA identified major concerns with efficacy, safety, and data interpretability.

How Exercise Transformed the Way These Doctors Practice

From personal experiences to injury to patient success stories, exercise never figured prominently in these doctors’ practice until now.

Trust and Teamwork Smooth Tough Clinical Conversations

Difficult conversations in dermatology become more productive when clinicians acknowledge concerns, avoid judgment, and seek common ground, an expert says.

Dupilumab Reduces Exacerbations in Kids With Type 2 Asthma

Dupilumab shows benefits in reducing severe exacerbations of asthma and improving outcomes in children with type 2 asthma and monoallergen or multiallergen sensitization.

Cell Therapy Trials Report More Data on Remissions, Relapses

Data from EULAR 2026 show that next-generation CAR T- and NK cell platforms induce powerful, drug-free clinical remissions in patients with highly refractory rheumatic diseases.

The Lasting Impact of Terminated Grants

Even with some grants restored, researchers say the deeper damage is harder to undo — and a proposed federal rule could make nonscientific control of science permanent.

Recommended News For You

According to JAMA, 5 alpha-reductase inhibitors are not significantly linked to prostate cancer mortality.

FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma

Smart exercise planning could boost recovery for people with cancer

Alternative Medicine for Breast Cancer: Study Raises Concern

Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL

Report: High risk of lung cancer from respirable crystalline silica even below the current occupational exposure limit

Patients with head and neck cancer who cannot receive cisplatin now have new hope.

Recommended Articles For You

Clinical Methods in Hematology and Quality Improvement 

Using Node Technology to Fight Breast Cancer: A New Hope for Early Detection 

Gene Therapy for Hemophilia: A New Hope on the Horizon 

Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Inner Thoughts of Leonard Bernstein, the "Maestro".

2.

Mobile prostate cancer screening clinic can ID the disease in disadvantaged men

3.

No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC

4.

Parents, teachers at Missouri school want answers after string of cancer diagnoses

5.

A promising medication could slow brain tumors in children.

1.

Future-Ready Cancer Screening: What Every Clinician Should Know in 2025

2.

Cancer Evolution and Therapeutic Resistance: Mechanisms, Clinical Insights, and Emerging Strategies

3.

Targeting Cancer Stem Cells in Solid Tumors: Mechanisms, Clinical Implications, and Therapeutic Advances

4.

Partial Gland Ablation in Prostate Cancer: Oncologic Outcomes in Intermediate-Risk Cases

5.

Generative AI for Adaptive Oncology Trial Design

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III

2.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

3.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC

4.

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

5.

Current Scenario of Cancer- The Incidence of Cancer in Men

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot